WIVI Vision is a technology company.
WIVI Vision has raised $4.0M across 1 funding round.
WIVI Vision has raised $4.0M in total across 1 funding round.
WIVI Vision has raised $4.0M in total across 1 funding round.
WIVI Vision's investors include Adara Ventures.
WIVI Vision is a Spanish health tech startup founded in 2016 that develops a patented hardware and software platform for assessing and treating visual dysfunctions, particularly non-strabismic binocular disorders like convergence insufficiency, tracking issues, and concussion-related vision problems.[3][5][7] The system serves eye care professionals (optometrists and ophthalmologists) and their patients—children from age 7 to adults—by collecting over 100 vision performance data points in 10-12 minutes via immersive 3D gamified interfaces, comparing results to norms, generating diagnostic reports, and delivering AI-powered, personalized rehabilitation training.[1][2][3][5] It solves the problem of inefficient, expensive traditional assessments (often limited to 4 parameters in one area) by providing comprehensive, objective analysis across five visual areas and real-time adaptive treatment, enabling faster diagnoses and outcomes while improving visual efficiency and quality of life for up to 40% of the population with undetected issues.[2][5][6]
The company has shown strong growth momentum, securing approvals like Spanish Ministry of Health medical device classification, expanding to over 70 centers in Spain, and forging partnerships with optical chains (e.g., NOG, General Óptica), hospitals, and institutions; it has also won grants (Neotec, Bridgehead) and accolades (Roche Summit, MedTech conferences).[6][7]
WIVI Vision emerged from E-Health Technical Solutions (EHTS), founded in 2016 in Bilbao, Spain, by Eva García Ramos (CEO with 25+ years in technology and visual health) and Dr. Juan Carlos Ondategui-Parra (optometrist with similar expertise and IBM Watson algorithm awards).[2][3][6][7] The duo identified a critical gap: society overlooks visual dysfunctions beyond glasses, relying on outdated, non-repetitive specialist tools that are costly and limited.[2][7] Drawing from EU-funded EyeWideVision project expertise in immersive 3D for cognitive/neural visual assessment, they created WIVI to integrate testing and training universally for children and adults.[2][5]
Early traction included 2019 milestones: selection for Roche Innovation Summit and Health startup programs, Neotec grant as an innovative firm, Bridgehead Grant win, and MedTech Investing Europe victory, validating the business and fueling expansion.[7]
WIVI Vision rides the wave of AI, immersive 3D, and gamification transforming optometry, addressing rising demand from aging populations, screen-heavy digital lifestyles, and post-concussion care needs.[6] Timing is ideal as vision disorders affect 40% globally yet go undetected, with 95-100% treatable via training—WIVI universalizes access beyond expensive specialists.[2][5] Market tailwinds include health tech investments (e.g., Adara VC backing) and partnerships with chains/hospitals, positioning it to set global standards.[3][6] It influences the ecosystem by enhancing eye care efficiency, enabling scalable personalized medicine, and bridging tech-visual health gaps, as seen in EU validation and U.S. pilots.[1][2]
WIVI Vision is poised for global scale, leveraging its 70+ Spanish foothold, regulatory wins, and tech edge to penetrate U.S./EU markets via demos and partnerships, targeting universal adoption as a vision health standard.[2][3][6] Trends like AI diagnostics, VR rehab, and tele-optometry will accelerate growth, especially with auto-updating software for emerging disorders. Its influence may evolve from niche innovator to ecosystem leader, empowering clinicians worldwide and redefining accessible visual care—echoing its mission to elevate quality of life through overlooked vision fixes.[5][7]
WIVI Vision has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $4.0M Series A | Adara Ventures |